- Trials with a EudraCT protocol (227)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
227 result(s) found for: Endocrine neoplasms benign.
Displaying page 1 of 12.
| EudraCT Number: 2018-003553-19 | Sponsor Protocol Number: IBCSG59-19/BIG18-02 | Start Date*: 2019-06-25 | ||||||||||||||||
| Sponsor Name:International Breat Cancer Study Group (IBCSG) | ||||||||||||||||||
| Full Title: A phase III open-label, multicenter, randomized trial of adjuvant palbociclib in combination with endocrine therapy versus endocrine therapy alone for patients with hormone receptor positive / HER2... | ||||||||||||||||||
| Medical condition: patients with hormone receptor positive / HER2-negative resected isolated locoregional recurrence of breast cancer | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: ES (Ongoing) FR (Trial now transitioned) HU (Trial now transitioned) AT (Trial now transitioned) IT (Trial now transitioned) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2012-003936-21 | Sponsor Protocol Number: TD-212-2308 | Start Date*: 2015-09-14 | ||||||||||||||||||||||||||
| Sponsor Name:Hôpital de Jolimont | ||||||||||||||||||||||||||||
| Full Title: A PROSPECTIVE MULTICENTRIC, PROOF OF CONCEPT STUDY TO EVALUATE THE VALUE OF 18-FDG-PET-SCAN ON TUMOUR RESPONSE IN PATIENTS WITH A PROGRESSIVE PANCREATIC ENDOCRINE TUMOUR RECEIVING A COMBINATION THE... | ||||||||||||||||||||||||||||
| Medical condition: Progressive well or moderately differentiated neuroendocrine tumour of the pancreas | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: BE (Prematurely Ended) | ||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||
| EudraCT Number: 2017-002960-42 | Sponsor Protocol Number: Yttrium-90-02 | Start Date*: 2017-11-15 | |||||||||||
| Sponsor Name:AZIENDA UNITÀ SANITARIA LOCALE DELLA ROMAGNA | |||||||||||||
| Full Title: 173/5000 Forse cercavi: Terapia radiometabolica recettoriale-mediata con [90Y-DOTA0-Tyr3]-octreotide (90Y-DOTATOC) nei tumori endocrini del tratto gastroenteropancreatico e bronchiale. (Yttrium-90... | |||||||||||||
| Medical condition: Patients with Somatostatin receptors Neoplasms | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2021-005919-30 | Sponsor Protocol Number: AK_NEN_DOTA-FDG_21 | Start Date*: 2022-09-21 | ||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Department of Clinical Physiology and Nuclear Medicine, Rigshospitalet | ||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients with Neuroendocrine Neoplasms | ||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Neuroendocrine neoplasms | ||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: DK (Trial now transitioned) | ||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2008-007348-32 | Sponsor Protocol Number: CSOM230D2203 | Start Date*: 2009-05-06 | |||||||||||
| Sponsor Name:Novartis Pharma Services AG | |||||||||||||
| Full Title: An open label, multicenter, single arm study of pasireotide LAR in patients with rare tumors of neuroendocrine origin | |||||||||||||
| Medical condition: The following tumors are included: 1. NETs of the pancreas or duodenum: Insulinoma, Gastrinoma, VIPoma, glucagonoma, 2. Pituitary NETs: Thyrotropic-pituitary adenoma (TSH), Gonadotropic adenoma, Pr... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) DE (Completed) IT (Completed) ES (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2007-001370-88 | Sponsor Protocol Number: IBCSG 35-07/ BIG 1-07 | Start Date*: 2007-11-06 | |||||||||||
| Sponsor Name:International Breast Cancer Study Group (IBCSG) | |||||||||||||
| Full Title: A phase III trial evaluating the role of continuous letrozole versus intermittent letrozole following 4 to 6 years of prior adjuvant endocrine therapy for postmenopausal women with hormone-receptor... | |||||||||||||
| Medical condition: Postmenopausal women who are disease-free following 4-6 years of prior adjuvant endocrine therapy with selective estrogen receptor modulator(s) (SERM) and/or aromatase inhibitor(s) (AI) for endocri... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: SE (Completed) BE (Completed) HU (Completed) IT (Completed) DE (Completed) DK (Completed) GB (Completed) ES (Completed) SI (Completed) GR (Completed) AT (Completed) IE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2012-000425-45 | Sponsor Protocol Number: | Start Date*: 2012-07-03 | |||||||||||||||||||||
| Sponsor Name: | |||||||||||||||||||||||
| Full Title: Effects of morning vs evening dosing on the pharmacokinetics and pharmacodynamics of sunitinib. | |||||||||||||||||||||||
| Medical condition: Renal Cell Cancer, GIST, pancreatic neuroendocrine tumor | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: NL (Ongoing) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2013-005479-42 | Sponsor Protocol Number: A301226 | Start Date*: 2014-06-04 | ||||||||||||||||
| Sponsor Name:Erasmus MC, Dept. Urology | ||||||||||||||||||
| Full Title: Pilot study: Toxicity of oestradiol for adjuvant endocrine therapy in locally confined prostate cancer | ||||||||||||||||||
| Medical condition: Prostate cancer | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male | |||||||||||||||||
| Trial protocol: NL (Ongoing) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2012-003155-11 | Sponsor Protocol Number: Yttrium-90-01 | Start Date*: 2012-07-17 | |||||||||||
| Sponsor Name:AZ. USL DI CESENA | |||||||||||||
| Full Title: Radiometabolic treatment with 90Y-DOTA0-Tyr3]-octreotide (90Y-DOTATOC) or [90Y-DOTA0-Tyr3-Thr8]-octreotate (90Y-DOTATATE)in tumours expressing somatostatin receptors | |||||||||||||
| Medical condition: Patient with tumour expressing somatostatine receptors | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2013-004728-13 | Sponsor Protocol Number: I3Y-MC-JPBL | Start Date*: 2014-07-09 | |||||||||||
| Sponsor Name:Eli Lilly and Company | |||||||||||||
| Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant with or without LY2835219, a CDK4/6 Inhibitor, for Women with Hormone Receptor Positive, HER2 Negative Locally Advanced ... | |||||||||||||
| Medical condition: Breast cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: IT (Trial now transitioned) BE (Trial now transitioned) ES (Ongoing) DE (Completed) FI (Completed) GR (Trial now transitioned) RO (Ongoing) DK (Completed) PL (Trial now transitioned) FR (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2010-023183-40 | Sponsor Protocol Number: CSOM230I2201 | Start Date*: 2011-06-28 | |||||||||||
| Sponsor Name:Novartis Pharma Services AG | |||||||||||||
| Full Title: A randomized, open-label phase II multicenter study evaluating the efficacy of oral Everolimus alone or in combination with Pasireotide LAR i.m. in advanced progressive pancreatic neuroendocrine tu... | |||||||||||||
| Medical condition: advanced progressive pancreatic neuroendocrine tumors (PNET) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Prematurely Ended) SE (Prematurely Ended) BE (Completed) DK (Prematurely Ended) DE (Completed) HU (Completed) ES (Completed) NL (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2013-001040-62 | Sponsor Protocol Number: GBG78/BIG1-13 | Start Date*: 2013-11-14 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:GBG Forschungs GmbH | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: Phase III study evaluating palbociclib (PD-0332991), a cyclin-dependent kinase (CDK) 4/6 inhibitor, in patients with hormone-receptor positive, HER2 normal primary breast cancer with high relapse r... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: About one-third of patient with hormone-receptor positive, HER2 negative breast cancer and residual disease after standard of care - including adequate surgery - have a substantial risk of relapse ... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: DE (Completed) ES (Completed) AT (Completed) IE (Completed) FR (Completed) GB (GB - no longer in EU/EEA) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2014-000888-41 | Sponsor Protocol Number: MetNET1trial | Start Date*: 2014-06-05 | ||||||||||||||||
| Sponsor Name:Fondazione IRCCS Istituto Nazionale dei tumori | ||||||||||||||||||
| Full Title: Activity and safety of Everolimus in combination with octreotide LAR and Metformin in patients with advanced pancreatic well-differentiated Neuroendocrine Tumors (pWDNETs): a Phase II, open, mono... | ||||||||||||||||||
| Medical condition: advanced/ or not resectable well differnciated pancreatic neuroendocrin tumor | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: IT (Completed) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2013-003927-12 | Sponsor Protocol Number: CHUBX2012/28 | Start Date*: 2014-03-03 | |||||||||||
| Sponsor Name:CHU de Bordeaux | |||||||||||||
| Full Title: Development of an innovative Gallium 68 radiolabeling of DOTATOC (68Ga-DOTATOC) for PET-CT imaging of neuro-endocrine tumors and preliminary clinical evaluation | |||||||||||||
| Medical condition: neuroendocrine tumors | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2004-002371-16 | Sponsor Protocol Number: D6997C00002 (9238IL/0064) | Start Date*: 2004-11-18 |
| Sponsor Name:AstraZeneca AB | ||
| Full Title: A Randomised, Double-Blind, Parallel-group, Multicentre, Phase III Study Comparing the Efficacy and Tolerability of Fulvestrant (FASLODEX™) 500 mg with Fulvestrant (FASLODEX™) 250 mg in Postmenopau... | ||
| Medical condition: Postmenopausal women with advanced breast cancer, progressing or relapsing after previous endocrine therapy | ||
| Disease: | ||
| Population Age: Elderly | Gender: Female | |
| Trial protocol: SK (Completed) CZ (Completed) HU (Completed) ES (Completed) IT (Completed) MT (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2005-004904-35 | Sponsor Protocol Number: Protocol2-55-52030-726 | Start Date*: 2006-08-14 | |||||||||||
| Sponsor Name:IPSEN PHARMA S.A.S. | |||||||||||||
| Full Title: Phase III, randomised, double-blind, stratified comparative, placebo controlled, parallel group, multicentre study to assess the effect of deep subcutaneous injections of lanreotide Autogel 120 mg ... | |||||||||||||
| Medical condition: Non functioning entero-pancreatic tumours | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) NL (Completed) BE (Completed) DK (Completed) CZ (Completed) GR (Completed) SE (Completed) DE (Completed) AT (Completed) IT (Completed) SK (Completed) ES (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2019-003897-24 | Sponsor Protocol Number: ICRCTSU/2019/10068 | Start Date*: 2020-07-06 | |||||||||||
| Sponsor Name:The Institute of Cancer Research | |||||||||||||
| Full Title: PreOperative Endocrine Therapy for Individualised Care with Abemaciclib | |||||||||||||
| Medical condition: Non-metastatic operable invasive ER+ HER2- breast cancer in post-menopausal women | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2018-003896-37 | Sponsor Protocol Number: ODO-TE-B201 | Start Date*: 2019-06-18 | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:Odonate Therapeutics, Inc. | ||||||||||||||||||||||||||||||||||||||
| Full Title: A Multinational, Multicenter, Phase 2 Study of Tesetaxel plus a Reduced Dose of Capecitabine in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer ... | ||||||||||||||||||||||||||||||||||||||
| Medical condition: breast cancer | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: ES (Prematurely Ended) | ||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2020-004035-24 | Sponsor Protocol Number: I3Y-MC-JPCW | Start Date*: 2021-04-26 | ||||||||||||||||
| Sponsor Name:Eli Lilly and Company | ||||||||||||||||||
| Full Title: eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib plus Standard Adjuvant Endocrine Therapy in Participants with High-Risk, Node-Positive, HR+, HER2+ Early Brea... | ||||||||||||||||||
| Medical condition: High-Risk, Node-Positive, HR+, HER2+ Breast Cancer | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: FR (Completed) BE (Completed) DE (Completed) FI (Prematurely Ended) AT (Completed) HU (Completed) GR (Completed) IT (Completed) ES (Prematurely Ended) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2021-005238-40 | Sponsor Protocol Number: EQ132-201 | Start Date*: 2022-05-11 | ||||||||||||||||||||||||||
| Sponsor Name:EQRx, Inc. | ||||||||||||||||||||||||||||
| Full Title: A Phase 2 Study to Evaluate the Safety and Efficacy of Lerociclib in Participants with Advanced Breast Cancer | ||||||||||||||||||||||||||||
| Medical condition: Metastatic Breast Cancer | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: BE (Completed) IT (Prematurely Ended) | ||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
